Synonyms: example 62 [WO2011048112A1] | LIK-066 | LIK066
Compound class:
Synthetic organic
Comment: Licogliflozin (LIK-066) is an orally bioactive inhibitor of sodium/glucose cotransporters 1 and 2 (SGLT1, SGLT2). It was developed by Novartis for the treatment of obesity, non-alcoholic steatohepatitis, and type 2 diabetes, but the program was discontinued in 2018 [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Licogliflozin (LIK-066) was progressed to clinical trials by Novartis for the treatment of obesity, non-alcoholic steatohepatitis, and type 2 diabetes. Unfortunately due to slow enrollment for Phase 2 trial NCT03152552, which would preclude the study being completed in a timely manner, Novartis decided to discontinue the study in 2018 [3]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01824264 | Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes | Phase 2 Interventional | Novartis | ||
NCT03152552 | A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure | Phase 2 Interventional | Novartis | Results from this study were published in 2020. Due to slow enrollment the study was prematurely terminated when only 142 patients had been recruited (125 were randomised). Becausete sample sizes were smaller thatn planned no firm conclusions could be made on the efficacy of licogliflozin in patients with T2DM and HF, although the 10 mg test dose did produce a significant effect. | 2 |